Arcus Biosciences

Arcus Biosciences(RCUS)

HAYWARD, CA
Biotechnology7 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Cancer Immunotherapies

Arcus Biosciences is a life sciences company focused on Cancer Immunotherapies.

Oncology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Determination of Metal Ion Serum Levels and Cytokines in Total Hip Replacement
Hip Replacement Arthroplasty
N/A
Clinical Trials (1)
NCT01394744Determination of Metal Ion Serum Levels and Cytokines in Total Hip Replacement
N/A
[14C]-etrumadenant
Healthy Participants
Phase 1
Phase 1
Clinical Trials (1)
NCT06191796Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
Phase 1
Phase 1
Clinical Trials (1)
NCT05154136A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants
Phase 1
Phase 1
AB801
Cancer
Phase 1
Clinical Trials (1)
NCT06004921A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT03719326A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Phase 1
Phase 1
Clinical Trials (1)
NCT06120075A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Phase 1
Phase 1
Clinical Trials (1)
NCT03720678A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies
Phase 1
Phase 1
Clinical Trials (1)
NCT06919991Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)
Phase 1
Phase 1
Phase 1
Clinical Trials (1)
NCT03629756A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Phase 1
Phase 1
Clinical Trials (1)
NCT05891171Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Phase 1
Phase 1
Clinical Trials (1)
NCT04892875A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
Phase 1
Phase 1
Clinical Trials (1)
NCT04575311A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT03677973A Study to Investigate the Safety of AB680 in Healthy Volunteers
Phase 1
Zimberelimab
Glioblastoma
Phase 1
Clinical Trials (1)
NCT04656535AB154 Combined With AB122 for Recurrent Glioblastoma
Phase 1
Phase 1
Clinical Trials (1)
NCT05536141A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT05999513A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers
Phase 1
Phase 1
Phase 1
Phase 1
Clinical Trials (1)
NCT07364214Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)
Phase 1
Phase 1
Clinical Trials (1)
NCT04104672A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
Phase 1
Phase 1
Clinical Trials (1)
NCT05117554Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers
Phase 1
Phase 1
Phase 1/2
ZIMBERELIMAB
Pancreatic Cancer
Phase 1/2
Clinical Trials (1)
NCT05419479Switch Maintenance in Pancreatic
Phase 1/2
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT05688215Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Phase 1/2
Phase 2
Clinical Trials (1)
NCT04791839Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Phase 2
Phase 2
Phase 2
Clinical Trials (1)
NCT05915442Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
Phase 2
Phase 2
Stereotactic body radiotherapy
Pancreatic Ductal Adenocarcinoma
Phase 2
Clinical Trials (1)
NCT06048484Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
Phase 2
Phase 2
Clinical Trials (1)
NCT07397611Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Phase 2
Phase 2
Phase 2
Clinical Trials (1)
NCT07283848Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
Phase 2
Phase 2
Zimberelimab
Melanoma
Phase 2
Clinical Trials (1)
NCT05130177Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
Phase 2
Etrumadenant
Rectal Cancer
Phase 2
Clinical Trials (1)
NCT05024097A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
Phase 2
Phase 2
Clinical Trials (1)
NCT05724563Domvanalimab and Zimberelimab in Advanced Liver Cancers
Phase 2
Phase 2
Phase 2
Clinical Trials (1)
NCT03821246Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
Phase 2
Zimberelimab
Lung Cancer
Phase 2
Phase 2
Phase 2
Phase 3
Phase 3
Phase 3
Phase 3
Clinical Trials (1)
NCT06608927Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 31 clinical trials
H-1B (2023): 7 approvals
SEC Filings: 2 available

Financials (FY2025)

Revenue
$117M4%
R&D Spend
$340M(291%)18%
Net Income
-$307M
Cash
$150M
Source: SEC 10-K Filing

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
7
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub